Intravesical chemotherapy (IVC) administered immediately following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer significantly decreases the likelihood of disease recurrence, findings of a new meta-analysis suggest.
The meta-analysis, by Nathan Perlis, MD, and colleagues at the University of Toronto, focused on 13 randomized, controlled trials that enrolled 2,548 adult patients. IVC immediately following TURBT significantly prolonged the recurrence-free interval (RFI) by 38%, researchers reported online ahead of print in European Urology. Early recurrences (within one year) were 12% less likely in IVC recipients. The investigators calculated that nine patients would need to receive IVC to prevent one early recurrence.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.